Aroda, Vanita R.

Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

Diabetes Prevention Program Research Group, Nathan, D. M., Knowler, W. C., Edelstein, S., Crandall, J. P., Dabelea, D., Goldberg, R. B., Kahn, S. E., Mather, K. J., Trandafirescu, G., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 128

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review

Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 126

Effects of Weight Loss, Weight Cycling, and Weight Loss Maintenance on Diabetes Incidence and Change in Cardiometabolic Traits in the Diabetes Prevention Program

Delahanty, L. M., Pan, Q., Jablonski, K. A., Aroda, V. R., Watson, K. E., Bray, G. A., Kahn, S. E., Florez, J. C., Perreault, L., Franks, P. W., et al. (2014) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsObesity, Physical Activity, Diet

Cited by 125

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 115

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 94

Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial

Blonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 85

Development of clinical trials to extend healthy lifespan

Justice, J. N., Niedernhofer, L., Robbins, P. D., Aroda, V. R., Espeland, M. A., Kritchevsky, S. B., Kuchel, G. A., & Barzilai, N. (2018) · Cardiovascular Endocrinology & Metabolism

Genetics, Aging, and Longevity in Model OrganismsTelomeres, Telomerase, and Senescence

Cited by 84

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences

Horowitz, M., Aroda, V. R., Han, J., Hardy, E., & Rayner, C. K. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 79

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 78

Metabolic and Hormonal Changes Induced by Pioglitazone in Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Clinical Trial

Aroda, V. R., Ciaraldi, T. P., Burke, P., Mudaliar, S., Clopton, P., Phillips, S., Chang, R. J., & Henry, R. R. (2009) · The Journal of Clinical Endocrinology & Metabolism

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 71

Metformin and Type 2 Diabetes Prevention

Aroda, V. R., & Ratner, R. E. (2018) · Diabetes Spectrum

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

The impact of physical activity on the prevention of type 2 diabetes: Evidence and lessons learned from the Diabetes Prevention Program, a long-standing clinical trial incorporating subjective and objective activity measures

Kriska, A. M., Rockette-Wagner, B., Edelstein, S. L., Bray, G. A., Delahanty, L. M., Hoskin, M. A., Horton, E. S., Venditti, E. M., Knowler, W. C., DPP Research Group, et al. (2021) · Diabetes Care

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Treating chronic diseases without tackling excess adiposity promotes multimorbidity

Sattar, N., McMurray, J. J. V., McInnes, I. B., Aroda, V. R., & Lean, M. E. J. (2023) · The Lancet Diabetes & Endocrinology

Chronic Disease Management StrategiesObesity, Physical Activity, Diet

Cited by 69

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 68

Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)

Perreault, L., Pan, Q., Aroda, V. R., Barrett-Connor, E., Dabelea, D., Dagogo-Jack, S., Hamman, R. F., Kahn, S. E., Mather, K. J., Knowler, W. C., et al. (2017) · Diabetic Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 55

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 39

Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence

Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact

Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 29

High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial

Aroda, V. R., Jørgensen, N. B., Kumar, B., Lingvay, I., Laulund, A. S., Buse, J. B., & trial investigators (2025) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 25

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist s in people with type 2 diabetes mellitus: A network meta‐analysis

Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 23

Safety and tolerability of glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program

Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 20

Intensive glycemic control improves long-term renal outcomes in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT)

Agrawal, L., Azad, N., Bahn, G. D., Reaven, P. D., Hayward, R. A., Reda, D. J., Emanuele, N. V., VADT Study Group, Abraira, C., Duckworth, W. C., et al. (2019) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 20

Reproducibility of a prediabetes classification in a contemporary population

Chadha, C., Pittas, A. G., Lary, C. W., Knowler, W. C., Chatterjee, R., Phillips, L. S., Aroda, V. R., Lewis, M. R., Pratley, R., Staten, M. A., et al. (2020) · Metabolism Open

Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 15